

**Table F-7. Harms/adverse effects in studies of risperidone adjuncts**

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
<b>Risperidone + piracetam</b>		
Appetite increase <sup>73</sup>	1 (7/20)	35%
Dry mouth <sup>73</sup>	1 (4/20)	20%
EPS/impaired movement <sup>73</sup>	1 (6/20)	30%
Gastrointestinal problems <sup>73</sup>	1 (4/20)	20%
Somnolence <sup>73</sup>	1 (23/20)	%
<b>Risperidone + amantadine</b>		
Appetite increase <sup>68</sup>	1(6/20)	30%
<b>Risperidone + buspirone</b>		
Appetite Increase <sup>61</sup>	1 (10/16)	61.1%
Somnolence <sup>61</sup>	1 (3/16)	18.75%
<b>Risperidone + celecoxib</b>		
Appetite Increase <sup>64</sup>	1 (3/20)	15%
Dizziness <sup>64</sup>	1 (2/20)	10%
GI <sup>64</sup>	1 (5/20)	25%

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Insomnia <sup>64</sup>	1 (2/20)	10%
Somnolence <sup>64</sup>	1 (3/20)	15%
EPS/impaired movement <sup>64</sup>	1 (10/20)	50%
<b>Risperidone + Galantamine</b>		
Agitation/nervousness/restlessness <sup>67</sup>	1 (4/20)	20%
Appetite Increase <sup>67</sup>	1 (8/20)	40%
Somnolence <sup>67</sup>	1 (2/20)	10%
<b>Risperidone + Ginkgo biloba</b>		
Agitation/nervousness/restlessness <sup>69</sup>	1 (8/23)	
Appetite decrease <sup>69</sup>	1 (3/23)	13%
Appetite Increase <sup>69</sup>	1 (6/23)	26.1%
EPS/impaired movement <sup>69</sup>	1 (5/23)	21.7%
GI symptoms <sup>69</sup>	1 (8/23)	34.8%
Somnolence <sup>69</sup>	1 (13/23)	56.5%
<b>Risperidone + memantine</b>		
Appetite increase <sup>65</sup>	1 (2/20)	10%
Dizziness <sup>65</sup>	1 (3/20)	15%
GI <sup>65</sup>	1 (5/20)	25%
Skin Changes <sup>65</sup>	1 (2/20)	10%
Somnolence <sup>65</sup>	1 (4/20)	20%
EPS/impaired movement <sup>65</sup>	1 (6/20)	30%
<b>Risperidone + N-acetylcysteine</b>		
Agitation/nervousness/restlessness <sup>63</sup>	1 (6/17)	35.3%
Appetite decrease <sup>63</sup>	1 (3/17)	17.6%
Appetite Increase <sup>63</sup>	1 (5/17)	29.4%
Dry mouth <sup>62</sup>	1 (2/20)	10%
EPS/impaired movement <sup>63</sup>	1 (7/20)	35%
Gastrointestinal problems <sup>62, 63</sup>	2 (23/37)	5.9%-30%
Headache <sup>62</sup>	1 (4/20)	20%
Somnolence <sup>63</sup>	1 (9/20)	45%
<b>Risperidone + Pentoxifylline</b>		
Agitation/nervousness/restlessness <sup>70</sup>	1 (2/20)	10%
Appetite increase <sup>70</sup>	1 (8/20)	40%
Dry mouth <sup>70</sup>	1 (2/20)	10%
Gastrointestinal problems <sup>70</sup>	1 (6/20)	30%
Somnolence <sup>70</sup>	1 (9/20)	45%
Weight gain <sup>70</sup>	1 (8/20)	40%
EPS/impaired movement <sup>70</sup>	1 (7/20)	25%
<b>Risperidone + Pioglitazone</b>		
Dizziness <sup>60</sup>	1 (2/20)	20%
Gastrointestinal problems <sup>60</sup>	1 (10/20)	50%
Headache <sup>60</sup>	1 (3/20)	15%
<b>Risperidone + Minocycline</b>		
Gastrointestinal problems <sup>71</sup>	1 (5/23)	8.6%-13%
Appetite increase <sup>71</sup>	1 (2/23)	8.6%
Dizziness <sup>71</sup>	1 (2/23)	8.6%
Headache <sup>71</sup>	1 (1/23)	4.3%
Insomnia <sup>71</sup>	1 (2/23)	8.6%
Sedation <sup>71</sup>	1 (3/23)	13%
<b>Risperidone + placebo</b>		
Agitation/nervousness/restlessness <sup>63, 66-70, 73</sup>	7 (18/138)	4.2%-20.8%
Appetite decrease <sup>61, 63-65, 67-70, 72, 73</sup>	10 (19/196)	5%-20%
Appetite increase <sup>61, 63-71, 73</sup>	11 (45/219)	8.6%-41.7%
Dizziness <sup>60, 64, 65, 69, 71, 72</sup>	6 (16/127)	5%-20%
Drooling/increased saliva <sup>66, 68, 69</sup>	3 (10/64)	5%-30%

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Dry mouth <sup>60-62, 69, 70, 73</sup>	6 (11/122)	4.2%-15%
EPS/impaired movement <sup>64-66, 69, 70, 72, 73</sup>	7 (45/144)	4.2%-45%
Gastrointestinal problems <sup>60, 62-73</sup>	13 (58/241)	4.3%-30%
Headache <sup>60, 62, 71</sup>	3 (6/63)	4.3%-15%
Infection/fever/cold/congestion symptoms <sup>69</sup>	1 (5/24)	20.8%
Insomnia <sup>64, 65, 71, 72</sup>	4 (10/83)	5%-25%
Paresthesia <sup>72</sup>	1 (5/20)	25%
Sedation <sup>71</sup>	1 (4/23)	17.4%
Skin Changes <sup>63, 65</sup>	2 (2/34)	5%-7.1%
Somnolence <sup>63-67, 69, 70, 72, 73</sup>	9 (59/178)	5%-45%
Weight Gain <sup>70</sup>	1 (7/20)	35%
<b>Risperidone + Riluzole</b>		
Agitation/nervousness/restlessness <sup>66</sup>	1 (7/20)	35%
Appetite decrease <sup>66</sup>	1 (2/20)	10%
Appetite Increase <sup>66</sup>	1 (12/20)	60%
Drooling/Increased Saliva <sup>66</sup>	1 (6/20)	60%
EPS/Impaired movement <sup>66</sup>	1 (4/20)	10%
Gastrointestinal problems <sup>66</sup>	1 (10/20)	50%
Somnolence <sup>66</sup>	1 (10/20)	50%
<b>Risperidone + Topiramate</b>		
Appetite decrease <sup>72</sup>	1 (7/20)	35%
Dizziness <sup>72</sup>	1 (4/20)	20%
Gastrointestinal problems <sup>72</sup>	1 (6/20)	30%
Insomnia <sup>72</sup>	1 (5/20)	25%
Paresthesia <sup>72</sup>	1 (5/20)	25%
Somnolence <sup>72</sup>	1 (8/20)	40%
EPS/impaired movement <sup>72</sup>	1 (9/20)	45%

\*Harms reported by more than one participant. EPS=extrapyramidal symptoms; GI=gastrointestinal